SHH and cancer: Deregulation of the Shh–GLI1 pathway has been showed to lead to tumorigenesis and aggressive phenotypes (progression, metastasis and therapeutic resistance) of numerous cancer types such as basal cell carcinomas (47), colorectal carcinoma (48), breast cancer (49), and bone and soft tissue sarcomas (50).